Two studies finalized in Oasmia Pharmaceutical’s Docecal programme

NEXT STORY
Bavarian Nordic Applauds Reauthorization of Key U.S. Biodefense Programs
PREV STORY
UPDATE – PREMIA and AmoyDx Announce Strategic Partnership to Establish Asia Cancer Clinical Genomic Network
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Shire plc : Director Declaration

Director Declaration April 3, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") ...

author_avatar
NASDAQ Market News

Aptose Biosciences to Participate at the Oppenheimer & Co. Inc. Boston Oncology Insight Summit and 1×1 Day

SAN DIEGO and TORONTO, July 09, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) ...

author_avatar
NASDAQ Market News

TG Therapeutics, Inc. Announces Umbralisib Clinical Data Presentation at the 54th Annual Meeting of the American Society of Clinical Oncology

CHICAGO, June 04, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced updated ...

author_avatar
NASDAQ Market News